Gonadorelin (2 mg Vial) Dosage Protocol

Gonadorelin (2 mg Vial) Dosage Protocol

Quickstart Highlights

Gonadorelin dosage supports the restoration of natural LH and FSH release from the pituitary gland, reactivating the hypothalamic‑pituitary‑gonadal (HPG) axis[1]. As a synthetic form of gonadotropin‑releasing hormone (GnRH), gonadorelin stimulates testosterone production in men and promotes ovulation in women when administered in short, pulsatile doses[2][3]. This educational protocol outlines a subcutaneous micro‑dosing approach using a practical dilution for accurate insulin‑syringe measurements.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 1 mg/mL concentration (1000 mcg/mL).
  • Typical dose range: 50–250 mcg per injection, 2–3 times weekly.
  • Easy measuring: At 1 mg/mL, 1 unit = 0.01 mL = 10 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Gonadorelin Vial

Dosing & Reconstitution Guide

Educational guide for reconstitution and periodic dosing

Standard / Maintenance Approach (2 mL = 1 mg/mL)

Route: Subcutaneous injection. Frequency: 2–3 times per week on non‑consecutive days (e.g., Mon/Wed/Fri or Tue/Thu/Sat).

Week/Phase Dose per Injection (mcg) Units (mL)
Weeks 1–2 (Initiation) 50 mcg 5 units (0.05 mL)
Weeks 3–4 (Titration) 100 mcg 10 units (0.10 mL)
Weeks 5–8 (Maintenance) 100–150 mcg 10–15 units (0.10–0.15 mL)

For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label concentration (1 mg/mL) and date; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Advanced / Post‑Cycle Support Approach

Route: Subcutaneous injection. Frequency: Daily or every other day for short cycles (limit to ≤14 consecutive days to avoid pituitary desensitization).

Week/Phase Dose per Injection (mcg) Units (mL)
Days 1–7 (Burst) 200 mcg 20 units (0.20 mL)
Days 8–14 (Taper) 100 mcg 10 units (0.10 mL)
Week 3+ (Optional Maintenance) 100 mcg 2–3×/wk 10 units (0.10 mL)

Important: Limit consecutive daily dosing to ≤14 days. Extended continuous administration may lead to GnRH receptor desensitization and reduced LH/FSH response[4].

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on a 4–8 week protocol with 2–3 injections per week.

  • Peptide Vials (Gonadorelin, 2 mg each):

    • 4 weeks (100 mcg × 3/wk) ≈ 1 vial
    • 6 weeks (100 mcg × 3/wk) ≈ 1 vial
    • 8 weeks (150 mcg × 3/wk) ≈ 2 vials
  • Insulin Syringes (U‑100, 30‑ or 50‑unit preferred):

    • Per week: 3 syringes
    • 4 weeks: 12 syringes
    • 6 weeks: 18 syringes
    • 8 weeks: 24 syringes
  • Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.

    • 4–6 weeks (1 vial): 2 mL → 1 × 10 mL bottle
    • 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
  • Alcohol Swabs: One for the vial stopper + one for the injection site each administration.

    • Per week: 6 swabs (2/injection × 3 injections)
    • 4 weeks: 24 swabs
    • 6 weeks: 36 swabs
    • 8 weeks: 48 swabs → recommend 1 × 100‑count box
Gonadorelin Vial
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

Concise summary of the periodic micro‑dosing regimen.

  • Goal: Stimulate endogenous LH and FSH release to support testosterone production and testicular function[1][5].
  • Schedule: Subcutaneous injections 2–3 times weekly for 4–8 weeks; limit daily dosing to ≤14 consecutive days.
  • Dose Range: 50–200 mcg per injection based on goals and response.
  • Reconstitution: 2.0 mL per 2 mg vial (1 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested periodic titration approach.

  • Start: 50–100 mcg per injection; assess tolerance before increasing.
  • Target: 100–150 mcg per injection, 2–3 times weekly.
  • Frequency: Non‑consecutive days (e.g., Mon/Wed/Fri) to mimic pulsatile GnRH release.
  • Cycle Length: 4–8 weeks; include off‑periods to maintain pituitary sensitivity.
  • Timing: Morning injections preferred; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks and avoid freeze–thaw.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document each dose, date, and site rotation to maintain consistency.
  • Limit continuous daily dosing to ≤14 days to prevent receptor desensitization[4].

How This Works

Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin‑releasing hormone (GnRH) secreted by the hypothalamus[1]. When administered in short, pulsatile fashion, it binds to GnRH receptors on pituitary gonadotrophs, triggering the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH)[2][3]. LH stimulates Leydig cells to produce testosterone in men and triggers ovulation in women, while FSH supports spermatogenesis and ovarian follicle development[5]. Unlike continuous GnRH agonist administration, which desensitizes receptors and suppresses gonadotropins, brief periodic dosing preserves the natural pulsatile signaling pattern[4][6].

Potential Benefits & Side Effects

Observations from clinical and preclinical literature.

  • Supports endogenous testosterone production by stimulating LH release[1][5].
  • May help maintain testicular volume and function during exogenous testosterone therapy[7].
  • Promotes spermatogenesis and fertility in hypogonadotropic hypogonadism when administered in pulsatile regimens[8][9].
  • Generally well tolerated; occasional mild injection‑site reactions (redness, itching, or swelling) may occur[10].
  • Possible transient headache or flushing shortly after injection[10].

Lifestyle Factors

Complementary strategies for best outcomes.

  • Maintain adequate sleep (7–9 hours) to support natural hormonal rhythms.
  • Pair with resistance training and balanced nutrition to optimize hormonal response.
  • Manage stress through relaxation techniques; chronic stress can impair HPG axis function.
  • Avoid excessive alcohol and limit endocrine disruptors where possible.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources[11].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12][13].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[14].

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References


  • PubMed
    — GnRH agonists: gonadorelin, leuprolide, and nafarelin – overview of pharmacology and clinical applications
    View Source

  • Mayo Clinic
    — Gonadorelin injection routes and indications for LH/FSH stimulation testing
    View Source

  • Wikipedia
    — Gonadorelin pharmacology, pulsatile dosing, and clinical history
    View Source

  • PMC
    — Gonadotropin‑releasing hormone analogs: pulsatile vs. continuous effects on FSH/LH
    View Source

  • PubMed
    — Gonadotropin treatment for male hypogonadotropic hypogonadism – spermatogenesis and fertility
    View Source

  • ScienceDirect
    — Gonadorelin agonist overview: initial stimulation and subsequent down‑regulation mechanisms
    View Source

  • PMC
    — Preserving fertility in the hypogonadal patient: hCG and GnRH therapy options
    View Source

  • PMC
    — Pulsatile gonadorelin pump induces earlier spermatogenesis in congenital HH men
    View Source

  • PubMed
    — Application of GnRH in hypogonadotropic hypogonadism: diagnostic and therapeutic aspects
    View Source

  • Drugs.com
    — Gonadorelin injectable: uses, side effects, and warnings
    View Source

  • PMC
    — Subcutaneous drug injection review: pharmacologic considerations
    View Source

  • CDC
    — Vaccine administration: subcutaneous route (angle/site; no aspiration)
    View Source

  • CDC (Subcut Injection PDF)
    — Technique diagram and site guidance for subcutaneous injections
    View Source

  • NCBI Bookshelf
    — Best practices for injection (asepsis, preparation, and administration)
    View Source

  • Pure Lab Peptides
    — Gonadorelin (2 mg) product page (quality and batch documentation)
    View Source